BROOKS LAB LTDBB

BROOKS LAB LTD

120.19INRR
+1.66+1.40%
At close at Mar 21, 10:29 GMT
INR
No trades
See on Supercharts

BROOKS fundamentals

Key facts

Market capitalization‪3.15 B‬INR
Basic EPS (TTM)−6.99INR
Founded2002
CEO
About

Brooks Laboratories Ltd. operates as a research and development driven pharmaceutical manufacturing company. It products include liquid injection, dry powder injection, carbapenem dry powder injectables, tablets, and oral suspension. The company was founded by Atul Ranchal and Rajesh Mahajan on January 23, 2002 and is headquartered in Mumbai, India.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪3.15 B‬‬
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.04x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
Price to sales ratio (P/S)
4.04x
Valuation ratios
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪1.30‬
‪2.60‬
‪3.90‬
‪5.20‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−58%‬
‪−46%‬
‪−34%‬
‪−22%‬
‪−10%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−100.00 M‬‬
‪0.00‬
‪‪100.00 M‬‬
‪‪200.00 M‬‬
‪‪300.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−70.00 M‬‬
‪0.00‬
‪‪70.00 M‬‬
‪‪140.00 M‬‬
‪‪210.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Drugs
Export Incentives
Other
By country
Period: 2023
India
International

Dividends

Dividend yield, history and sustainability

BROOKS does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪25.00 M‬‬
‪‪50.00 M‬‬
‪‪75.00 M‬‬
‪‪100.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
Assets
Liabilities